tradingkey.logo
tradingkey.logo
Search

Edgewise Therapeutics Inc

EWTX
Add to Watchlist
38.430USD
-2.690-6.54%
Close 07-31 16:00ETQuotes delayed by 15 min
4.13BMarket Cap
LossP/E TTM

EWTX Income Statement

You can find the annual or quarterly income statement of Edgewise Therapeutics Inc here for insights into the performance and operational efficiency of Edgewise Therapeutics Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2020Q2
FY2020Q1
Operating expenses
17.75%54.12M
22.92%55.98M
15.89%46.86M
11.82%42.61M
32.24%45.96M
34.49%45.54M
37.28%40.43M
50.39%38.11M
35.20%34.75M
53.37%33.86M
61.27%29.45M
53.65%25.34M
73.37%25.70M
72.20%22.08M
39.66%18.26M
57.66%16.49M
116.22%14.83M
102.11%12.82M
258.93%13.08M
164.34%10.46M
111.11%6.86M
--6.34M
--3.64M
--3.96M
--3.25M
R&D expenses
16.04%42.65M
19.86%43.59M
16.32%37.48M
9.38%33.56M
32.73%36.76M
31.38%36.37M
35.47%32.22M
56.86%30.68M
39.33%27.69M
66.65%27.68M
71.20%23.79M
57.71%19.56M
78.68%19.88M
82.79%16.61M
40.63%13.89M
57.77%12.40M
107.54%11.12M
76.84%9.09M
205.13%9.88M
116.02%7.86M
80.65%5.36M
--5.14M
--3.24M
--3.64M
--2.97M
Depreciation, depletion, and amortization
-3.07%537.00K
-16.53%525.00K
-2.97%523.00K
8.96%523.00K
17.12%554.00K
30.23%629.00K
20.04%539.00K
13.21%480.00K
142.56%473.00K
448.86%483.00K
349.00%449.00K
337.11%424.00K
134.94%195.00K
12.82%88.00K
56.25%100.00K
90.20%97.00K
5.06%83.00K
56.00%78.00K
28.00%64.00K
13.33%51.00K
97.50%79.00K
--50.00K
--50.00K
--45.00K
--40.00K
Operating profit
-17.75%-54.12M
-22.92%-55.98M
-15.89%-46.86M
-11.82%-42.61M
-32.24%-45.96M
-34.49%-45.54M
-37.28%-40.43M
-50.39%-38.11M
-35.20%-34.75M
-53.37%-33.86M
-61.27%-29.45M
-53.65%-25.34M
-73.37%-25.70M
-72.20%-22.08M
-39.66%-18.26M
-57.66%-16.49M
-116.22%-14.83M
-102.11%-12.82M
-258.93%-13.08M
-164.34%-10.46M
-111.11%-6.86M
---6.34M
---3.64M
---3.96M
---3.25M
Net non-operating interest income (expenses)
Non-operating interest income
-1.14%5.10M
-1.96%5.76M
-1.76%6.19M
-1.74%6.50M
-17.13%5.16M
58.05%5.88M
68.57%6.30M
70.80%6.61M
117.31%6.23M
39.60%3.72M
389.40%3.74M
812.74%3.87M
1626.51%2.87M
2014.29%2.66M
501.57%764.00K
296.26%424.00K
295.24%166.00K
6200.00%126.00K
12600.00%127.00K
3466.67%107.00K
-33.33%42.00K
--2.00K
--1.00K
--3.00K
--63.00K
Income before tax
-20.14%-49.01M
-26.61%-50.22M
-19.15%-40.67M
-14.66%-36.12M
-43.03%-40.80M
-31.58%-39.66M
-32.73%-34.13M
-46.71%-31.50M
-24.90%-28.52M
-55.26%-30.14M
-46.95%-25.71M
-33.62%-21.47M
-55.78%-22.84M
-52.92%-19.41M
-35.13%-17.50M
-55.19%-16.07M
-115.11%-14.66M
-100.19%-12.70M
-255.55%-12.95M
-161.84%-10.35M
-113.97%-6.81M
---6.34M
---3.64M
---3.95M
---3.19M
Income tax
----
----
----
----
----
--0.00
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income after tax
-20.14%-49.01M
-26.61%-50.22M
-19.15%-40.67M
-14.66%-36.12M
-43.03%-40.80M
-31.58%-39.66M
-32.73%-34.13M
-46.71%-31.50M
-24.90%-28.52M
-55.26%-30.14M
-46.95%-25.71M
-33.62%-21.47M
-55.78%-22.84M
-52.92%-19.41M
-35.13%-17.50M
-55.19%-16.07M
-115.11%-14.66M
-100.19%-12.70M
-255.55%-12.95M
-161.84%-10.35M
-113.97%-6.81M
---6.34M
---3.64M
---3.95M
---3.19M
Net income from continuous operations
-20.14%-49.01M
-26.61%-50.22M
-19.15%-40.67M
-14.66%-36.12M
-43.03%-40.80M
-31.58%-39.66M
-32.73%-34.13M
-46.71%-31.50M
-24.90%-28.52M
-55.26%-30.14M
-46.95%-25.71M
-33.62%-21.47M
-55.78%-22.84M
-52.92%-19.41M
-35.13%-17.50M
-55.19%-16.07M
-115.11%-14.66M
-100.19%-12.70M
-255.55%-12.95M
-161.84%-10.35M
-113.97%-6.81M
---6.34M
---3.64M
---3.95M
---3.19M
Net income attributable to controlling interests
-20.14%-49.01M
-26.61%-50.22M
-19.15%-40.67M
-14.66%-36.12M
-43.03%-40.80M
-31.58%-39.66M
-32.73%-34.13M
-46.71%-31.50M
-24.90%-28.52M
-55.26%-30.14M
-46.95%-25.71M
-33.62%-21.47M
-55.78%-22.84M
-52.92%-19.41M
-35.13%-17.50M
-55.19%-16.07M
-115.11%-14.66M
-100.19%-12.70M
-255.55%-12.95M
-161.84%-10.35M
-113.97%-6.81M
---6.34M
---3.64M
---3.95M
---3.19M
Net income attributable to common shareholders
-20.14%-49.01M
-26.61%-50.22M
-19.15%-40.67M
-14.66%-36.12M
-43.03%-40.80M
-31.58%-39.66M
-32.73%-34.13M
-46.71%-31.50M
-24.90%-28.52M
-55.26%-30.14M
-46.95%-25.71M
-33.62%-21.47M
-55.78%-22.84M
-52.92%-19.41M
-35.13%-17.50M
-55.19%-16.07M
-115.11%-14.66M
-100.19%-12.70M
-255.55%-12.95M
-161.84%-10.35M
-113.97%-6.81M
---6.34M
---3.64M
---3.95M
---3.19M
Basic earnings per share
-6.69%-0.46
-13.11%-0.47
-5.96%-0.39
-2.18%-0.34
-31.66%-0.43
10.02%-0.42
10.21%-0.36
0.57%-0.34
9.76%-0.33
-51.79%-0.47
-20.05%-0.41
-4.62%-0.34
-21.99%-0.36
-19.50%-0.31
-28.41%-0.34
-54.05%-0.32
-106.53%-0.30
-92.38%-0.26
-243.27%-0.26
-152.86%-0.21
-113.96%-0.14
---0.13
---0.08
---0.08
---0.07
Diluted earnings per share
-6.69%-0.46
-13.11%-0.47
-5.96%-0.39
-2.18%-0.34
-31.66%-0.43
10.02%-0.42
10.21%-0.36
0.57%-0.34
9.76%-0.33
-51.79%-0.47
-20.05%-0.41
-4.62%-0.34
-21.99%-0.36
-19.50%-0.31
-28.41%-0.34
-54.05%-0.32
-106.53%-0.30
-92.38%-0.26
-243.27%-0.26
-152.86%-0.21
-113.96%-0.14
---0.13
---0.08
---0.08
---0.07
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Edgewise Therapeutics Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing EWTX stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Edgewise Therapeutics Inc's net income for the year?

Edgewise Therapeutics Inc posted -167.79M in net income for fiscal year 2025.

How much net income did Edgewise Therapeutics Inc post in the last quarter?

Edgewise Therapeutics Inc reported -49.01M in net income for the latest quarter。

What was Edgewise Therapeutics Inc's annual operating profit?

Edgewise Therapeutics Inc's operating income was -191.41M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.